← Leaderboards
Cyrus M Ghajar
Fred Hutchinson Cancer Center
$4,796,533
Attributed
$5,074,965
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,074,965 · 5
By mechanism
R01$4,356,405 · 2
U01$556,865 · 1
P30$161,695 · 2
Top collaborators
- Shelly R. Peyton1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Elizabeth Mary Swisher$14,985,539
- Dan H. Barouch$218,203,090
- James Douglas Thomas$129,738
- Tessa Amanda Arends$124,308
Others in their field
Other Emerging Leaders on “Malignant Breast Neoplasm”
- Greg Yothers · University Of Chicago$35,003,821
- Olwen Hahn · Brigham And Women'S Hospital$32,076,706
- Leonard Freedman · Leidos Biomedical Research, Inc.$21,750,066
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Leonard Freedmand · Leidos Biomedical Research, Inc.$12,635,631
- Jessica Scott · Sloan-Kettering Inst Can Research$10,553,540
Research focus
Malignant Breast NeoplasmSiteNeoplasm MetastasisNeoplastic CellBreast Cancer CellLiverLungBrainPreventIn VivoInnovationMediatingBreast Cancer PatientSignal TransductionBreast Cancer MetastasisMetastasis PreventionKnock-DownBone MarrowBlood VesselsTissuesResistanceResponseBreast Cancer PreventionMalignant Neoplasms
Grant awards (15)
Stiffness-mediated genetic selection of cells$556,865
U01 · FY2025 · CA
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$402,600
R01 · FY2025 · CA · contact PI
Breast and Ovary Cancers$85,511
P30 · FY2025 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$460,702
R01 · FY2024 · CA · contact PI
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$382,471
R01 · FY2024 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$475,250
R01 · FY2023 · CA · contact PI
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$394,548
R01 · FY2023 · CA · contact PI
Research Program: Breast & Ovary Cancers$76,184
P30 · FY2023 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$475,250
R01 · FY2022 · CA · contact PI
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$273,745
R01 · FY2022 · CA · contact PI
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$120,803
R01 · FY2022 · CA · contact PI
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance$402,600
R01 · FY2021 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$323,315
R01 · FY2021 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$161,633
R01 · FY2021 · CA · contact PI
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain$483,488
R01 · FY2020 · CA · contact PI